deltatrials
Terminated PHASE1 INTERVENTIONAL 2-arm NCT01548924

Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors

Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel Versus Priming With BIBF 1120 BIBF 1120 Followed by Plus Paclitaxel in Breast Cancer With HER-2 Negative Correlative Proteomic Studies. and Dynamic Image

Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Conditions Solid Tumors
Interventions Dovitinib Dovitinib + Paclitaxel
Updated 7 times since 2017 Last updated: Apr 15, 2020 Started: Apr 30, 2012 Primary completion: Feb 28, 2013 Completion: Aug 31, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Drug toxicity

Other Solid Tumors trials with similar outcome

Browse all Solid Tumors trials

This PHASE1 trial investigates Solid Tumors and is currently terminated or withdrawn. Centro Nacional de Investigaciones Oncologicas CARLOS III leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotTerminated~Jun 2018 – ~May 2020 · 23 months · monthly snapshotTerminated~May 2020 – ~Jan 2021 · 8 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 8 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  5. May 2020 — Jan 2021 [monthly]

    Terminated PHASE1

▶ Show 2 earlier versions

  1. Jun 2018 — May 2020 [monthly]

    Terminated PHASE1

  2. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE1

    First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Centro Nacional de Investigaciones Oncologicas CARLOS III
  • Hospital Universitari de Bellvitge
  • Hospital Universitario de Fuenlabrada
  • M.D. Anderson Cancer Center
Data source: Centro Nacional de Investigaciones Oncologicas CARLOS III

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations